MD, University of Massachusetts Med School, Worcester, MA
BS, Chemistry, Boston College, Chestnut Hill, MA
1989 to Present:
Oncologist / Hematologist, Attending Physician, Marshfield Clinic Inc. - Marshfield Center, Marshfield, WI
1989 to Present:
Attending Physician, Marshfield Clinic Inc. - Stevens Point Center, Stevens Point, WI
1989 to Present:
Attending Physician, MCHS Hospitals Inc. d/b/a Marshfield Medical Center, Marshfield, WI
1989 to Present:
Attending Physician, Ascension St. Michael's Hospital, Stevens Point, WI
2001 to 2017:
Medical Director, Hematopoietic Stem Cell Transplant Program, MCHS Hospitals Inc. d/b/a Marshfield Medical Center, Marshfield, WI
1989 to 2016:
Attending Physician, Marshfield Clinic at James Beck Cancer Center, Rhinelander, WI
1999 to 2015:
Medical Director, Medical Oncology Services, St. Michael's Hospital, Stevens Point, WI
1994 to 2013:
Medical Director, Oncology Services, St. Joseph's Hospital, Marshfield, WI
1994 to 2010:
Chairman, Department of Clinical Oncology, Marshfield Clinic - Marshfield Center, Marshfield, WI
1987 to 1989:
Attending Physician, Hematology-Medical Oncology Service, Department of Medicine, Wilford Hall USAF Medical Center, Lackland AFB, TX
1984 to 1989:
Clinical Assistant Professor, Uniform Services - University of Health Sciences, Bethesda, MD
1982 to 1984:
Chief, Internal Medicine, USAF Hospital Moody, Moody AFB, GA
1982 to Present:
American Board of Internal Medicine
1987 to Present:
American Board of Internal Medicine - Medical Oncology
1988 to Present:
American Board of Internal Medicine - Hematology
American Society of Clinical Oncology, Member
American Society of Hematology, Member
Wisconsin Medical Society, Member
Mercier RJ, Neal GD, Mattox DE, Gates GA, Pomeroy TC, Von Hoff DD. (1987 December). Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck. CANCER. 60(11):2609-2612.
Mercier RJ, Thompson JM, Harman GS, Messerschmidt GL. (1988 January). Recurrent hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in Hodgkin's disease. Am J Med. 84(1):165-168.
McGlasson DL, Mercier RJ, Potempa LF, Patterson WR. (1990). Platelet neutralization procedures: atypical results with Factory V deficiency with and wthout the presence of an inhibitor. Clin Lab Sci. (3):119-121.
Rushing DA, Reding DJ, Mercier RJ, Tipping SJ, Friedenberg WR, Plank DM. (1994). High dose chemotherapy with stem cell reinfusion. Proceedings of ASCO. 13 :1.
Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA,...Messerschmidt GL [including Mercier RJ.] (1994 October). et al. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study. Bone Marrow Transplant. 14(4):595-600.
Rushing DA, Reding DJ, Mercier RJ, Friedenberg WR, Tipping SJ, Miedema I, Plank DM. (1995 May). High dose chemotherapy with ICE and stem cell reinfusion for metastatic breast cancer. Proceedings of ASCO. 14 :1.
Friedenberg WR, Miller HJ, Marx JJ, Schloesser LL, Reding DJ, Mazza JJ,...Cassileth PA [including Hocking WG, Mercier RJ.] (1995 April). The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy. Am J Clin Oncol. 18(2):105-110.
Rushing DA, Reding DJ, Mercier RJ, Tipping SJ, Friedenberg WR, Plank GS,...Musser CJ [including Plank DM.] (1996). High dose chemotherapy for breast cancer: Ifosfamide, VP-16, Carboplatin dose escalation. CD34+ cell correlation to marrow recovery. Proceedings of ASCO. 15 :1.
Mercier RJ, Reding DJ, Rushing DA, Tipping SJ, Friedenberg WR, Plank DM,...Musser CJ. (1996 March). High dose chemotherapy with peripheral blood stem cell re-infusion dose escalation study of Ifosfamide, VP-16, Carboplatin in metastatic breast cancer. Proceedings of ASCO. 15 :147.
Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier RJ, Dakhil S,...Levin VA. (1997 March). TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 15(3):1063-1070.
Mercier RJ, Reding DJ, Thomalla JV, Fischer VV, Lappe KA, Zhang KQi. (1998). Prostate cancer (PC) tumor characteristics in a prevalence population at a community cancer center (CCC). Proceedings of ASCO. 17 :1.
Mercier RJ, Reding DJ. (1998). Prostate cancer tumor characteristics in a prevalence population at a community cancer center. Proceedings of ASCO. 17 :1.
Mazza JJ, Birhiray RE, Clouse LH, Friedenberg WR, Hocking WG, Mercier RJ, Reding DJ. (2001 December). Five-year single institution study of acute adult leukemia. 43rd ASH Annual Meeting.
Rai K, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA,...Brettman L. (2002 September). Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 20(18):3891-3897.
Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M,...Shepherd FA [including Mercier RJ.] (2005 February). Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol. 23(4):842-849.
Onitilo AA, Skorupa A, Lal A, Ronish E, Mercier RJ, Islam R, Lazarchick J. (2006 July). Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost. 96(1):84-87.
Islam R, Rahman M, Mian AHuq, Ege HMD, Reding DJ, Shakoor MAbdus,...Mercier RJ [including Liang H.] (2012 July). Incidence of Non-Neutropenic Infection (NNI) in Patients With Follicular Lymphoma and Small Lymphocytic Lymphoma: The Effects of Rituximab Therapy International Journal of Hematology and Oncology.. 22(4):1-7.
Bapani S, Epperla N, Kasirye Y, Mercier RJ, Garcia-Montilla RJ. (2013 June). ADAMTS13 Deficiency and Thrombotic Thrombocytopenic Purpura Associated with Trimethoprim-Sulfamethoxazole Clinical Medicine & Research. 11(2):86-90.
Sanfelippo MJ, Mazza JJ, Mercier RJ. (2014 December). Symptomatic factor XIII deficiency with normal urea solubility test. Clin Lab. 60 :2099-2102.